SG11202005319PA - Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid - Google Patents

Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid

Info

Publication number
SG11202005319PA
SG11202005319PA SG11202005319PA SG11202005319PA SG11202005319PA SG 11202005319P A SG11202005319P A SG 11202005319PA SG 11202005319P A SG11202005319P A SG 11202005319PA SG 11202005319P A SG11202005319P A SG 11202005319PA SG 11202005319P A SG11202005319P A SG 11202005319PA
Authority
SG
Singapore
Prior art keywords
amylin
compositions
aqueous solution
receptor agonist
injectable aqueous
Prior art date
Application number
SG11202005319PA
Inventor
You-Ping Chan
Alexandre Geissler
Romain Noel
Richard Charvet
Nicolas Laurent
Original Assignee
Adocia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1761808A external-priority patent/FR3074682B1/en
Priority claimed from FR1855943A external-priority patent/FR3083085B1/en
Application filed by Adocia filed Critical Adocia
Priority claimed from PCT/EP2018/083943 external-priority patent/WO2019110788A1/en
Publication of SG11202005319PA publication Critical patent/SG11202005319PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment
SG11202005319PA 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid SG11202005319PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762606139P 2017-12-07 2017-12-07
FR1761808A FR3074682B1 (en) 2017-12-07 2017-12-07 COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTION SOLUTION COMPRISING AMYLINE, AN AMYLINE RECEPTOR AGONIST OR AN AMYLINE ANALOG AND A CO-POLYAMINOACID
FR1855943A FR3083085B1 (en) 2018-06-29 2018-06-29 COMPOSITIONS IN THE FORM OF AN AQUEOUS SOLUTION FOR INJECTION CONSISTING OF AMYLINE, AN AMYLINE RECEPTOR AGONIST OR ANALOGUE OF AMYLINE AND A CO-POLYAMINOACID
PCT/EP2018/083943 WO2019110788A1 (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid

Publications (1)

Publication Number Publication Date
SG11202005319PA true SG11202005319PA (en) 2020-07-29

Family

ID=64661389

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005319PA SG11202005319PA (en) 2017-12-07 2018-12-07 Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid

Country Status (10)

Country Link
US (1) US11129877B2 (en)
EP (1) EP3740227A1 (en)
JP (1) JP2021505616A (en)
KR (1) KR20200106890A (en)
CN (1) CN111683674A (en)
AU (1) AU2018380901A1 (en)
BR (1) BR112020011479A2 (en)
CA (1) CA3084699A1 (en)
MA (1) MA51600A (en)
SG (1) SG11202005319PA (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021505607A (en) * 2017-12-07 2021-02-18 アドシア An injectable solution at pH 7 containing at least one basal insulin with a pI of 5.8-8.5 and a copolyamino acid with carboxylate charge and hydrophobic radicals.
TW201938190A (en) 2017-12-07 2019-10-01 法商阿道洽公司 Injectable solution at PH 7 comprising at least one basal insulin wherein the PI is comprised from 5.8 to 8.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals
EP3858373A1 (en) 2020-01-31 2021-08-04 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8720115D0 (en) 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
IT1219712B (en) 1988-06-14 1990-05-24 Ausimont Spa HETEROCYCLIC PEROXIDE WITH HETERATOME "N" AMID
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
FR2672598A1 (en) 1991-02-11 1992-08-14 Adir NOVEL N-MYRISTOYLTRANSFERASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
HU222249B1 (en) 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Process for producing amyline antagonistic peptide derivatives and pharmaceutical preparatives containing them
EP0717635B1 (en) 1993-09-07 2000-11-15 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US7312196B2 (en) 1997-01-08 2007-12-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
US6410511B2 (en) 1997-01-08 2002-06-25 Amylin Pharmaceuticals, Inc. Formulations for amylin agonist peptides
FR2801226B1 (en) 1999-11-23 2002-01-25 Flamel Tech Sa COLLOIDAL SUSPENSION OF SUBMICRONIC PARTICLES FOR VECTORIZATION OF ACTIVE INGREDIENTS AND METHOD OF PREPARATION
FR2840614B1 (en) 2002-06-07 2004-08-27 Flamel Tech Sa POLYAMINOACIDS FUNCTIONALIZED BY ALPHA-TOCOPHEROL AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
FR2843117B1 (en) * 2002-07-30 2004-10-15 Flamel Tech Sa POLYAMINOACIDS FUNCTIONALIZED BY AT LEAST ONE HYDROPHOBIC GROUP AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
FR2855521B1 (en) 2003-05-28 2005-08-05 Flamel Tech Sa POLYAMINOACIDES FUNCTIONALIZED BY AT LEAST ONE YDROPHOBIC GROUP AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS.
FR2860516B1 (en) * 2003-10-03 2006-01-13 Flamel Tech Sa TELECHELIC HOMOPOLYAMINOACIDES FUNCTIONALIZED BY HYDROPHOBIC GROUPS AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
FR2873704B1 (en) * 2004-07-30 2006-12-08 Flamel Technologies Sa POLYAMINOACIDES FUNCTIONALIZED BY HYDROPHOBIC GRAFTS CARRYING AN ANIONIC CHARGE AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
US8084493B1 (en) * 2005-01-04 2011-12-27 Gp Medical, Inc. Pharmaceutical composition of peptide drug and enzyme-inhibition compounds
EP1996224B1 (en) 2006-03-15 2012-11-07 Novo Nordisk A/S Mixtures of amylin and insulin
FR2910318B1 (en) 2006-12-20 2009-07-03 Flamel Technologies Sa DISPERSION OF POLYAMINOACIDS IN A CONTINUOUS LIPID PHASE
FR2915748B1 (en) * 2007-05-03 2012-10-19 Flamel Tech Sa POLYGLUTAMIC ACIDS FUNCTIONALIZED BY CATIONIC GROUPS AND HYDROPHOBIC GROUPS AND THEIR APPLICATIONS, IN PARTICULAR THERAPEUTIC
US9173991B2 (en) 2007-07-02 2015-11-03 Roche Diabetes Care, Inc. Device for drug delivery
US20110082080A1 (en) 2007-10-12 2011-04-07 Curedm Group Holdings, Llc Compositions and methods of using the human proislet peptide receptor
EP2078713A1 (en) 2007-12-28 2009-07-15 QuoNova GmbH Inhibitors of biofilm formation of gram-positive and gram-negative bacteria
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
TWI480070B (en) 2011-04-21 2015-04-11 Univ Kaohsiung Medical Conformations of divergent peptides with mineral binding affinity
EA027744B1 (en) 2011-10-31 2017-08-31 Ксерис Фармасьютикалс, Инк. Formulations for the treatment of diabetes mellitus
FR2985428B1 (en) 2012-01-09 2016-05-27 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACIDE
BR112014016889A8 (en) * 2012-01-09 2017-07-04 Adocia composition in the form of an aqueous injectable solution ph is comprised between 6.0 and 8.0 and unit dose formulation with ph comprised between 7 and 7.8
FR2985429B1 (en) 2012-01-09 2016-07-29 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A SUBSTITUTED POLYAMINOACID OBTAINED BY A CONTROLLED POLYMERIZATION PROCESS
FR3001896B1 (en) * 2013-02-12 2015-07-03 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WHERE THE ISO-ELECTRIC POINT IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIC ANIONIC POLYMER
EP3102241B1 (en) 2014-02-03 2019-04-17 Eidgenössiche Technische Hochschule Zürich Small molecule drug conjugates
WO2017211917A1 (en) 2016-06-07 2017-12-14 Adocia Compositions in the form of an injectable aqueous solution, comprising human glucagon and a statistical copolyamino acid
FR3052072A1 (en) 2016-06-07 2017-12-08 Adocia PH 7 INJECTABLE SOLUTION COMPRISING AT LEAST ONE BASIC INSULIN WITH A PI BETWEEN 5.8 AND 8.5 AND A CO-POLYAMINOACIDE CARRYING CARBOXYLATE LOADS AND HYDROPHOBIC RADICALS
US10463717B2 (en) 2016-12-27 2019-11-05 Adocia Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog, and a co-polyamino acid
JP2021505607A (en) * 2017-12-07 2021-02-18 アドシア An injectable solution at pH 7 containing at least one basal insulin with a pI of 5.8-8.5 and a copolyamino acid with carboxylate charge and hydrophobic radicals.

Also Published As

Publication number Publication date
CN111683674A (en) 2020-09-18
US20190328842A1 (en) 2019-10-31
US11129877B2 (en) 2021-09-28
CA3084699A1 (en) 2019-06-13
AU2018380901A1 (en) 2020-06-11
MA51600A (en) 2020-11-25
EP3740227A1 (en) 2020-11-25
AU2018380901A2 (en) 2020-09-03
BR112020011479A2 (en) 2020-11-17
KR20200106890A (en) 2020-09-15
JP2021505616A (en) 2021-02-18

Similar Documents

Publication Publication Date Title
IL275146A (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
HK1251901A1 (en) Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
IL275463A (en) Tlr7/8 antagonists and uses thereof
ZA201905306B (en) Aerosol¿generating system with case
SG11202005319PA (en) Compositions in the form of an injectable aqueous solution comprising amylin, an amylin receptor agonist or an amylin analog and a copolyamino acid
IL272232A (en) Glp-1 compositions and uses thereof
SG11201700152QA (en) Stable aqueous fluoropolymer coating composition
IL247854A0 (en) Muscarinic receptor antagonists, compositions comprising same and uses thereof
IL275184A (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
IL275206A (en) Dried implant composition and injectable aqueous implant formulation
IL281938A (en) Stable semaglutide compositions and uses thereof
ZA201907833B (en) Heteroarylphenylaminoquinolines and analogues
IL253600A0 (en) Insulin analogues and compositions comprising same
SG11201707900TA (en) Intermodal container limiting pollution of the environment
IL269388A (en) Npra agonists, compositions, and uses thereof
GB202002129D0 (en) stable freshening compositions and products comprising the same
IL268997A (en) Compositions comprising pgi2-receptor agonists and processes for the preparation thereof
SG11202005320VA (en) Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
EP3409292A4 (en) Stabilized aqueous composition comprising chondroitin sulfate and hyaluronic acid
IL262036A (en) Hyaluronic acid conjugates and uses thereof
GB201806462D0 (en) Container with efferverscent action
GB201715402D0 (en) Aqueous coating composition
GB201714409D0 (en) Oligonucleotides and analogues thereof
SI3381457T1 (en) Physiologically active composition
IL273967A (en) Aqueous compositions comprising bilastine and mometasone